Effect of the direct renin inhibitor aliskiren on urinary albumin excretion in spontaneous type 2 diabetic KK- Ay mouse

International Journal of Nephrology

Volumn 2013, Issue , 2013, Pages

  Furukawa, Masako ^a   Gohda, Tomohito ^a   Hagiwara, Shinji ^a   Tanimoto, Mitsuo ^a   Horikoshi, Satoshi ^a   Funabiki, Kazuhiko ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879326693     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2013/519130     Document Type: Article

References (46)

1. Mathew A., Cunard R., Sharma K., Antifibrotic treatment and other new strategies for improving renal outcomes. Contributions to Nephrology 2011 170 217 227 2-s2.0-79959271839 10.1159/000325671
2. Choudhury D., Tuncel M., Levi M., Diabetic nephropathy-a multifaceted target of new therapies. Discovery Medicine 2010 10 54 406 415 2-s2.0-79952468846
3. Hagiwara S., Makita Y., Gu L., Tanimoto M., Zhang M., Nakamura S., Kaneko S., Itoh T., Gohda T., Horikoshi S., Tomino Y., Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrology Dialysis Transplantation 2006 21 3 605 615 2-s2.0-33644869129 10.1093/ndt/gfi208 (Pubitemid 43372905)
4. Ohara I., Tanimoto M., Gohda T., Yamazaki T., Hagiwara S., Murakoshi M., Aoki T., Toyoda H., Ishikawa Y., Funabiki K., Horikoshi S., Tomino Y., Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK- Ay /Ta mice. Nephron 2011 117 4 e124 e132 2-s2.0-77957780608 10.1159/000320284
5. Moon J. Y., Tanimoto M., Gohda T., Hagiwara S., Yamazaki T., Ohara I., Murakoshi M., Aoki T., Ishikawa Y., Lee S. H., Jeong K. H., Lee T. W., Ihm C. G., Lim S. J., Tomino Y., Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK- Ay /Ta mice. American Journal of Physiology 2011 300 6 F1271 F1282 2-s2.0-79958143772 10.1152/ajprenal.00065.2010
6. Ito T., Tanimoto M., Yamada K., Kaneko S., Matsumoto M., Obayashi K., Hagiwara S., Murakoshi M., Aoki T., Wakabayashi M., Gohda T., Funabiki K., Maeda K., Horikoshi S., Tomino Y., Glomerular changes in the KK- Ay /Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006 11 1 29 35 2-s2.0-33645361420 10.1111/j.1440-1797.2006.00543.x
7. Brewster U. C., Perazella M. A., The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. American Journal of Medicine 2004 116 4 263 272 2-s2.0-1242351306 10.1016/j.amjmed.2003.09.034 (Pubitemid 38224234)
8. Luft F. C., Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Current Opinion in Nephrology and Hypertension 2002 11 1 59 66 2-s2.0-0036142504 10.1097/00041552-200201000-00009 (Pubitemid 34053339)
9. Wolf G., Angiotensin II as a mediator of tubulointerstitial injury. Nephrology Dialysis Transplantation 2000 15 supplement 6 61 63 2-s2.0-0033653419
10. Brown M. J., Aliskiren. Circulation 2008 118 7 773 784 2-s2.0-50349094508 10.1161/CIRCULATIONAHA.108.787630
11. Jensen C., Herold P., Brunner H. R., Aliskiren: the first renin inhibitor for clinical treatment. Nature Reviews Drug Discovery 2008 7 5 399 410 2-s2.0-42949109643 10.1038/nrd2550 (Pubitemid 351619112)
12. Yamamoto E., Kataoka K., Dong Y. F., Nakamura T., Fukuda M., Tokutomi Y., Matsuba S., Nako H., Nakagata N., Kaneko T., Ogawa H., Kim-Mitsuyama S., Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009 54 3 633 638 2-s2.0-70349251477 10.1161/HYPERTENSIONAHA.109. 133884
13. Riche D. M., Minor D. S., Holdiness A. S., East H. E., An issue of dependence: implications from the Aliskiren in the evaluation of proteinuria in diabetes (AVOID) trial. Journal of Clinical Hypertension 2009 11 2 89 93 2-s2.0-60549100908 10.1111/j.1751-7176.2008.00069.x
14. Parving H. H., Brenner B. M., McMurray J. J., de Zeeuw D., Haffner S. M., Solomon S. D., Chaturvedi N., Persson F., Nicolaides M., Richard A., Xiang Z., Armbrecht J., Pfeffer M. A., Baseline characteristics in the aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). Journal of the Renin-Angiotensin-Aldosterone System 2012 13 3 387 393 10.1177/1470320311434818
15. Van Kooten C., Langers A. M. J., Bruijn J. A., Daha M. R., Role of tubular cells in progressive renal disease. Kidney and Blood Pressure Research 1999 22 1-2 53 61 2-s2.0-0032978527 10.1159/000025909 (Pubitemid 29243447)
16. Han S. Y., Jee Y. H., Han K. H., Kang Y. S., Kim H. K., Han J. Y., Kim Y. S., Cha D. R., An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrology Dialysis Transplantation 2006 21 9 2406 2416 2-s2.0-33750121618 10.1093/ndt/gfl238 (Pubitemid 44644511)
17. Ronco P., Chatziantoniou C., Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney International 2008 74 7 873 878 2-s2.0-51849139372 10.1038/ki.2008.349
18. Iwai M., Kanno H., Tomono Y., Inaba S., Senba I., Furuno M., Mogi M., Horiuchi M., Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK- Ay mice. Journal of Hypertension 2010 28 7 1471 1481 2-s2.0-77954386779 10.1097/HJH.0b013e32833bc420
19. Fryer R. M., Rakestraw P. A., Nakane M., Dixon D., Banfor P. N., Koch K. A., Wu-Wong J. R., Reinhart G. A., Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron 2007 106 4 p76 p81 2-s2.0-34547410327 10.1159/000104875 (Pubitemid 47172363)
20. Fan Q., Liao J., Kobayashi M., Yamashita M., Gu L., Gohda T., Suzuki Y., Wang L. N., Horikoshi S., Tomino Y., Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrology Dialysis Transplantation 2004 19 12 3012 3020 2-s2.0-19944426573 10.1093/ndt/gfh499 (Pubitemid 40057622)
21. Ozawa Y., Kobori H., Suzaki Y., Navar L. G., Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. American Journal of Physiology 2007 292 1 F330 F339 2-s2.0-33846259795 10.1152/ajprenal.00059.2006 (Pubitemid 46105273)
22. Tesch G. H., MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. American Journal of Physiology 2008 294 4 F697 F701 2-s2.0-44949130856 10.1152/ajprenal.00016.2008
23. Phillips A. O., Steadman R., Morrisey K., Martin J., Eynstone L., Williams J. D., Exposure of human renal proximal tubular cells to glucose leads to accumulation of type IV collagen and fibronectin by decreased degradation. Kidney International 1997 52 4 973 984 2-s2.0-0030820465 (Pubitemid 27435830)
24. Ronco P., Lelongt B., Piedagnel R., Chatziantoniou C., Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Seminars in Nephrology 2007 27 3 352 362 2-s2.0-34249052899 10.1016/j.semnephrol.2007.02.006 (Pubitemid 46802918)
25. Zhang S. X., Wang J. J., Lu K., Mott R., Longeras R., Ma J. X., Therapeutic potential of angiostatin in diabetic nephropathy. Journal of the American Society of Nephrology 2006 17 2 475 486 2-s2.0-33645456579 10.1681/ASN.2005020217
26. Inada A., Nagai K., Arai H., Miyazaki J. I., Nomura K., Kanamori H., Toyokuni S., Yamada Y., Bonner-Weir S., Weir G. C., Fukatsu A., Seino Y., Establishment of a diabetic mouse model with progressive diabetic nephropathy. American Journal of Pathology 2005 167 2 327 336 2-s2.0-25144442812 (Pubitemid 43026090)
27. Sun S. Z., Wang Y., Li Q., Tian Y. J., Liu M. H., Yu Y. H., Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chinese Medical Journal 2006 119 10 814 821 2-s2.0-33744474294 (Pubitemid 43796810)
28. McLennan S. V., Kelly D. J., Cox A. J., Cao Z., Lyons J. G., Yue D. K., Gilbert R. E., Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002 45 2 268 275 2-s2.0-0036189833 10.1007/s00125-001-0730-4 (Pubitemid 34208390)
29. Dixon A., Maric C., 17 β -Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor- β protein expression and signaling. American Journal of Physiology 2007 293 5 F1678 F1690 2-s2.0-36048988128 10.1152/ajprenal.00079.2007 (Pubitemid 350086005)
30. Eddy A. A., Molecular insights into renal interstitial fibrosis. Journal of the American Society of Nephrology 1996 7 12 2495 2508 2-s2.0-0030419494 (Pubitemid 27469555)
31. Thomson S. E., McLennan S. V., Kirwan P. D., Heffernan S. J., Hennessy A., Yue D. K., Twigg S. M., Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy. Journal of Diabetes and its Complications 2008 22 4 284 294 2-s2.0-45849122111 10.1016/j.jdiacomp.2007.07.001 (Pubitemid 351885491)
32. Fornoni A., Striker L. J., Zheng F., Striker G. E., Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002 51 2 499 505 2-s2.0-0036066931 (Pubitemid 34764809)
33. Singh R., Song R. H., Alavi N., Pegoraro A. A., Singh A. K., Leehey D. J., High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor- β 1. Experimental Nephrology 2001 9 4 249 257 2-s2.0-0034943382 (Pubitemid 32620209)
34. Bai Y., Wang L., Li Y., Liu S., Li J., Wang H., Huang H., High ambient glucose levels modulates the production of MMP-9 and α 5(IV) collagen by cultured podocytes. Cellular Physiology and Biochemistry 2006 17 1-2 57 68 2-s2.0-33644995630 10.1159/000091464
35. Lupia E., Elliot S. J., Lenz O., Zheng F., Hattori M., Striker G. E., Striker L. J., IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 1999 48 8 1638 1644 2-s2.0-0032785644 10.2337/diabetes.48.8.1638 (Pubitemid 29356874)
36. Diamantt M., Hanemaaijer R., Verheijen J. H., Smit J. W. A., Radder J. K., Lemkes H. H. P. J., Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabetic Medicine 2001 18 5 423 424 2-s2.0-0034913347 (Pubitemid 32679395)
37. Tashiro K., Koyanagi I., Ohara I., Ito T., Saitoh A., Horikoshi S., Tomino Y., Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. Journal of Clinical Laboratory Analysis 2004 18 3 206 210 2-s2.0-2342632543 10.1002/jcla.20024 (Pubitemid 38585800)
38. Lauhio A., Sorsa T., Srinivas R., Stenman M., Tervahartiala T., Stenman U. H., Grönhagen-Riska C., Honkanen E., Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Annals of Medicine 2008 40 4 312 320 2-s2.0-42449126565 10.1080/07853890801923746 (Pubitemid 351563934)
39. Kanauchi M., Nishioka H., Nakashima Y., Hashimoto T., Dohi K., Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Japanese Journal of Nephrology 1996 38 3 124 128 2-s2.0-0030098550 (Pubitemid 126501302)
40. Dharmani M., Mustafa M. R., Achike F. I., Sim M. K., Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. European Journal of Pharmacology 2007 561 1-3 144 150 2-s2.0-33947195336 10.1016/j.ejphar.2007.01.037 (Pubitemid 46435855)
41. Ritz E., Haxsen V., Angiotensin II and oxidative stress: an unholy alliance. Journal of the American Society of Nephrology 2003 14 11 2985 2987 2-s2.0-0142182710 10.1097/01.ASN.0000096784.86791.21 (Pubitemid 37305663)
42. Nguyen G., Delarue F., Burcklé C., Bouzhir L., Giller T., Sraer J. D., Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. Journal of Clinical Investigation 2002 109 11 1417 1427 2-s2.0-0036266596 10.1172/JCI200214276 (Pubitemid 34596167)
43. Huang Y., Noble N. A., Zhang J., Xu C., Border W. A., Renin-stimulated TGF- β 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney International 2007 72 1 45 52 2-s2.0-34347350179 10.1038/sj.ki.5002243 (Pubitemid 47014443)
44. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R. T., Yu L., Noble N. A., Border W., Renin increases mesangial cell transforming growth factor- β 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney International 2006 69 1 105 113 2-s2.0-30944469631 10.1038/sj.ki.5000011 (Pubitemid 43117745)
45. Feldt S., Maschke U., Dechend R., Luft F. C., Muller D. N., The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. Journal of the American Society of Nephrology 2008 19 4 743 748 2-s2.0-42249089770 10.1681/ASN.2007091030
46. Feldman D. L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R. L., Mueller D. N., Feldt S., Cumin F., Maniara W., Persohn E., Schuetz H., Danser A. H. J., Nguyen G., Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 Rats. Hypertension 2008 52 1 130 136 2-s2.0-46449118638 10.1161/HYPERTENSIONAHA.107.108845